Last reviewed · How we verify
NCT04827563
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
trial testing EndoPAT in Multiple Myeloma in 50 participants. Terminated before completion.
8 September 2025
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 22 March 2021 |
| Primary completion | 8 September 2025 |
| Estimated completion | 8 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- EndoPAT
- Blood Pressure Cuff
- Echocardiogram
- Quality of Life Assessment
- Blood Tests — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Shortness of Breath — all drugs for Shortness of Breath →
- Dyspnea — all drugs for Dyspnea →
- Cardiotoxicity — all drugs for Cardiotoxicity →
Sponsor
University of Chicago
Who can join
18 and older, any sex, with Multiple Myeloma or Shortness of Breath. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04827563
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of EndoPAT
Trials testing the same drug.
- NCT05955729 — Effect of a Short Nap During the Night Shift of Healthcare Workers on Endothelial Function · NA · completed
- NCT05672134 — Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction · Phase 2 · completed
- NCT02992106 — Evolution of Maternal Weight During Pregnancy and Influence on the Endothelial Function in Her Offspring · NA · completed
- NCT01803984 — MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction · terminated
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04827563 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 4 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04827563.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing